Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.

Front Oncol

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, United States.

Published: January 2023

Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into the treatment landscape of TNBC have led to improved outcomes in a subset of patients both in the early stage and metastatic settings. However, a large portion of patients with TNBC remain resistant to immune checkpoint inhibitors and have limited treatment options beyond cytotoxic chemotherapy. The interplay between the anti-tumor immune response and tumor metabolism contributes to immunotherapy response in the preclinical setting, and likely in the clinical setting as well. Specifically, tumor glycolysis and lactate production influence the tumor immune microenvironment through creation of metabolic competition with infiltrating immune cells, which impacts response to immune checkpoint blockade. In this review, we will focus on how glucose metabolism within TNBC tumors influences the response to immune checkpoint blockade and potential ways of harnessing this information to improve clinical outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872136PMC
http://dx.doi.org/10.3389/fonc.2022.1061789DOI Listing

Publication Analysis

Top Keywords

immune checkpoint
16
tumor glycolysis
8
immunotherapy response
8
triple negative
8
negative breast
8
breast cancer
8
checkpoint inhibitors
8
response immune
8
checkpoint blockade
8
immune
7

Similar Publications

Background: Accurate data on the prognosis of bone metastases are necessary for appropriate treatment. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of gene mutation-negative non-small cell lung cancer (GMN-NSCLC).

Aim: To investigate the prognostic factors in patients with bone metastases from GMN-NSCLC following ICI use.

View Article and Find Full Text PDF

Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying early changes in the immune system was critical to directing the therapeutic choice and improving the clinical outcome.

View Article and Find Full Text PDF

Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis.

Front Immunol

January 2025

Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: Circadian rhythms in the immune system and anti-tumor responses are underexplored in cancer immunotherapy. Despite the success of immune checkpoint inhibitors (ICIs) in treating advanced biliary tract cancers (BTCs), not all patients benefit. This study examined whether the timing of ICI administration affects outcomes in advanced BTC patients.

View Article and Find Full Text PDF

Breast cancer continues to be a significant global health challenge due to its heterogeneity and propensity for therapeutic resistance. The current tumor, node, and metastasis (TNM) staging and molecular classification systems are limited in capturing the full biological complexity of breast cancer. Myeloid differentiation primary response protein 88 (MyD88), a key adaptor protein in inflammatory signaling pathways, has been implicated in various oncogenic processes.

View Article and Find Full Text PDF

Identification of the oncogenic role and clinical implication of in Colon Adenocarcinoma.

J Cancer

January 2025

Department of Oncology, Geriatric Medical Center, Wuxi Second Geriatric Hospital, Wuxi Huishan Second People's Hospital, Wuxi, 214174, Jiangsu, China.

Colorectal carcinoma (CRC) is a highly prevalent and life-threatening disease with multi-stage progression, characterized by diverse molecular expression patterns at distinct stages, making treatment particularly challenging. Early detection and diagnosis of CRC are vital and can greatly benefit from the discovery of effective biomarkers. Researchers have identified novel gene signatures that play pivotal roles in specific CRC types or stages.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!